- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02202070
Botox for Treatment of TMJ Disorder With Bruxism (TMJ)
Phase 1 Study of Role of Botox in Myofascial Temporomandibular Disorder
Hypothesis: Myofascial temporomandibular joint disorder and related symptoms are associated with mandibular condyle and temporal fossa overloading secondary to temporalis and masseter muscle hyperactivity and spasm
This study will examine the use of onabotulinumtoxinA (Botox) to treat myofascial pain disorder in patients with bruxism who frequently exhibit signs of temporomandibular joint disorder (TMD) in a double blind cross-over randomized clinical trial by injecting 50 units Botox in temporalis and masseter muscles in 32 patients with 6 months follow up.
The objective of the proposed study will be to establish the safety and efficacy of botox in treating TMD associated with bruxism. By the time patients reach the specialists office, most have failed maximal conservative therapies, including non-chew diet, night guard, oral analgesics, muscle relaxants, physical therapy, and a portion have even undergone more invasive procedures, such as manipulation under anesthesia, arthroscopy, and arthroplasty surgeries with limited improvement or recurrence. Primary outcome of the study will be 50% reduction in pain. Secondary outcomes will be 50% reduction in surgical therapy, 25% increase in maximal inter-incisal opening (MIO). The investigators look forward to working with you on the proposed study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- aged 18-65 persons with a diagnosis of myofascial temporomandibular joint disorder refractory to conservative treatment for 6 months
Exclusion Criteria:
- pregnancy
- rheumatoid arthritis
- ankylosing spondylitis
- psoriatic arthritis
- fibromyalgia
- neuropathic pain
- pain of dental origin
- muscle relaxant use
- aminoglycoside use
- prior Botox use
- neuropathic pain
- trigeminal neuralgia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Botox injection first, followed by placebo
50 units Botox injection in masseter and temporalis muscles in the first 3 months, then second injection of normal saline at placebo in second 3 months
|
Other Names:
|
Experimental: Placebo injection first, followed Botox
Injection of normal saline at placebo in first 3 months, then 50 units Botox injection in masseter and temporalis muscles in the second 3 months.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
50% reduction in pain
Time Frame: 6 months
|
Patients will be seen in clinic every 3 months and asked to fill out questionaire.
Questionaire will include with visual analogue scale (VAS) average pain over previous week, month
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
25% increase in maximal opening at incisors
Time Frame: 6 months
|
Patients will be seen in clinic every 3 months.
Providers will objectively measure maximal opening at incisors (MOI), lateral and anterior mandible excursion on clinical exam.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
50% reduction in progression of disease to surgery
Time Frame: 6 months
|
Patients will be monitored for TMJ arthoscopic and arthoplasty procedures
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Alan A Harvey, DMD, Assistant Professor, Department of Otolaryngology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Stomatognathic Diseases
- Tooth Diseases
- Jaw Diseases
- Craniomandibular Disorders
- Mandibular Diseases
- Syndrome
- Disease
- Fibromyalgia
- Joint Diseases
- Myofascial Pain Syndromes
- Bruxism
- Temporomandibular Joint Disorders
- Temporomandibular Joint Dysfunction Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- AAHEJB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bruxism
-
Karabuk UniversityRecruiting
-
Riyadh Colleges of Dentistry and PharmacyUnknownNocturnal BruxismSaudi Arabia
-
Damascus UniversityCompletedNocturnal BruxismSyrian Arab Republic
-
University of California, San FranciscoWithdrawn
-
University of Nove de JulhoUnknown
-
Universidade Federal do Rio de JaneiroUnknown
-
CES UniversityNot yet recruitingSleep Bruxism, Childhood
-
Aydin Adnan Menderes UniversityCompleted
-
Dominik EttlinMerz PharmaceuticalsNot yet recruiting
-
Federal University of PelotasUnknown
Clinical Trials on onabotulinumtoxinA
-
AllerganCompletedGlabellar Lines | Crow's Feet Lines | Facial RhytidesGermany, Canada, United States, France
-
AllerganCompletedGlabellar Lines | Crow's Feet Lines | Facial RhytidesGermany, Canada, United States, France
-
Northwell HealthWithdrawn
-
Henry Ford Health SystemActive, not recruitingGlabellar Frown LinesUnited States
-
Buddhist Tzu Chi General HospitalCompleted
-
Dartmouth-Hitchcock Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at Birmingham and other collaboratorsRecruitingOveractive Bladder | Urinary Incontinence in Old Age | Urgency Urinary IncontinenceUnited States
-
Seoul National University HospitalIpsen; Medical Research Collaborating Center, Seoul, KoreaCompletedCervical DystoniaKorea, Republic of
-
Universita di VeronaMarialuisa GandolfiUnknown
-
The First Affiliated Hospital of University of...Not yet recruiting
-
Karolinska InstitutetCompletedCovid-19 | Bleeding | Thromboembolic EventsSweden